• Intra-Cellular Therapies EPS for the quarter ending December 31, 2024 was $-0.15, a 50% decline year-over-year.
• Intra-Cellular Therapies 2024 annual EPS was $-0.72, a 50.68% decline from 2023.
• Intra-Cellular Therapies 2023 annual EPS was $-1.46, a 46.32% decline from 2022.
• Intra-Cellular Therapies 2022 annual EPS was $-2.72, a 22.29% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.